Cargando…

Nutrient Induced Type 2 and Chemical Induced Type 1 Experimental Diabetes Differently Modulate Gastric GLP-1 Receptor Expression

T2DM patients demonstrate reduced GLP-1 receptor (GLP-1R) expression in their gastric glands. Whether induced T2DM and T1DM differently affect the gastric GLP-1R expression is not known. This study assessed extrapancreatic GLP-1R system in glandular stomach of rodents with different types of experim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bloch, Olga, Broide, Efrat, Ben-Yehudah, Gilad, Cantrell, Dror, Shirin, Haim, Rapoport, Micha J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393893/ https://www.ncbi.nlm.nih.gov/pubmed/25893200 http://dx.doi.org/10.1155/2015/561353

Ejemplares similares

Simultaneous analyses of carbohydrate-mediated serum GLP-1 and GLP-2 and duodenal receptor expression in children with and without celiac disease
por: Rachmiel, Marianna, et al.
Publicado: (2019)

Coronary atherosclerosis severity is closely associated with decreased GLP-1R positivity among CD16(+) pro-inflammatory and patrolling monocyte subsets
por: Bloch, Olga, et al.
Publicado: (2021)

The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion
por: Hjørne, Anna Pii, et al.
Publicado: (2022)

Expression of Duodenal Iron Transporter Proteins in Diabetic Patients with and without Iron Deficiency Anemia
por: Broide, Efrat, et al.
Publicado: (2018)

Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice
por: Broide, Efrat, et al.
Publicado: (2020)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension
por: Rapoport, Micha, et al.
Publicado: (2021)

Corrigendum to “Expression of Duodenal Iron Transporter Proteins in Diabetic Patients with and without Iron Deficiency Anemia”
por: Broide, Efrat, et al.
Publicado: (2018)

Do inflammatory bowel disease patient preferences from treatment outcomes differ by ethnicity and gender? A cross-sectional observational study
por: Naftali, Timna, et al.
Publicado: (2022)

The Anorectic Effect of GLP-1 in Rats Is Nutrient Dependent
por: Sandoval, Darleen, et al.
Publicado: (2012)

Cost effectiveness of routine duodenal biopsies in iron deficiency anemia
por: Broide, Efrat, et al.
Publicado: (2016)

Achalasia During Pregnancy: Proposed Management Algorithm Based on a Thorough Literature Review
por: Vosko, Sergei, et al.
Publicado: (2021)

The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
por: Richter, Vered, et al.
Publicado: (2023)

New-Onset of Crohn’s Disease Is Associated with Antistreptolysin O Positive Titers
por: Bermont, Anton, et al.
Publicado: (2020)

The Relationship between Gender, Severity of Disease, Treatment Type, and Employment Outcome in Patients with Inflammatory Bowel Disease in Israel
por: Naftali, Timna, et al.
Publicado: (2018)

Lymphoid follicles in children with Helicobacter pylori-negative gastritis
por: Broide, Efrat, et al.
Publicado: (2017)

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
por: Deacon, Carolyn F.
Publicado: (2012)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress
por: Ceriello, Antonio, et al.
Publicado: (2015)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
por: Bae, Choon Sang, et al.
Publicado: (2017)

Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
por: Salehi, Marzieh, et al.
Publicado: (2010)

Bedouin Children With Celiac Disease: Less Symptoms but More Severe Histological Features at Presentation
por: Yerushalmi, Baruch, et al.
Publicado: (2020)

The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons
por: Richter, Vered, et al.
Publicado: (2022)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
por: Nauck, Michael A., et al.
Publicado: (2020)

Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
por: Al-Sadawi, Mohammed A., et al.
Publicado: (2023)

Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4
por: Lietzau, Grazyna, et al.
Publicado: (2016)

Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches
por: Szolomajer, János, et al.
Publicado: (2022)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
por: Umapathysivam, Mahesh M, et al.
Publicado: (2023)

Angiotensin II Type 1 Receptor-Dependent GLP-1 and PYY Secretion in Mice and Humans
por: Pais, Ramona, et al.
Publicado: (2016)

Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2013)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
por: Saraiva, José Francisco Kerr, et al.
Publicado: (2021)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v5tpmo0816f2vsvq8759h4qlo1